Jazz Pharmaceuticals Accelerates Oncology Business Layout, Can It Reverse the Growth Slump

Vertex Pharmaceuticals在股市表现亮眼
Published on: Oct 28, 2026
Author: Amy Liu

Jazz Pharmaceuticals (JAZZ) is at a critical stage of business transformation. Although Xywav, used to treat cataplexy in patients with narcolepsy, remains the main revenue driver, it faces competitive pressure, while the rapid growth of the oncology business and the successive approval of new products provide the company with a diversification path. Over the past five years, Jazz Pharmaceuticals has faced multiple challenges, with mediocre revenue growth performance. But the pharmaceutical company is accelerating its push into oncology and has thereby improved its financial performance.

Second-Quarter Results Show Strong Performance

Jazz Pharmaceuticals’ second-quarter revenue grew 16% year over year to $1.2 billion, a fairly strong performance with contributions from multiple products. Among them, Xywav, used to treat cataplexy in patients with narcolepsy, recorded sales of $471.2 million, up 13.5% year over year. Xywav has performed well in replacing the company’s former blockbuster Xyrem. Since Xyrem faced generic competition in the United States in 2023, it has no longer made a significant contribution to the company’s performance. Another key growth driver, Epidiolex, used to treat certain rare epileptic seizures, saw second-quarter revenue grow 16% year over year to $292.1 million. The drug’s medium-term outlook is relatively solid, and it is not expected to face generic competition within the next five years. The company is seeking to launch the product in other countries such as Japan.

In the second quarter, Jazz Pharmaceuticals’ oncology business revenue grew nearly 32% year over year to $362.3 million. Among them, the lung cancer drug Zepzelca was the best-selling product in the oncology business, with sales of $105.8 million, up 42% year over year. The question is whether the company’s oncology business can continue to perform well in the medium term.

What Are the Future Prospects

Jazz Pharmaceuticals has conducted more clinical trials in oncology than in any other field, and one of the more promising products is Ziihera. The drug was first approved in the United States in 2024 and received a label expansion in August this year for the treatment of certain patients with gastroesophageal adenocarcinoma. Ziihera is also being tested in at least six other potential indications. Ziihera’s second-quarter sales contribution was not significant, which is not surprising given its short time on the market. But with the recent label expansion and potential additional indications, it could become an important growth driver for the company. Other candidate products also have similar potential. Last year, the company also obtained U.S. approval for Modeyso, which is used to treat diffuse midline glioma, while other clinical trials may support label expansion.

The recent launches of Jazz’s oncology products look promising, and the company’s deep pipeline provides important opportunities to expand market coverage and drive sales growth, which is expected to gradually reduce its dependence on Xywav. By 2031, the company may have a stronger portfolio of approved products, delivering sustained sales and earnings growth. Some argue that for investors willing to hold for at least five years, the stock is attractive at current levels. In addition to Epidiolex being expected to drive sales growth for some time, the company’s oncology pipeline is also improving, and Jazz currently trades at a forward price-to-earnings ratio of only 10.9 times, compared with an average of 19.2 times for healthcare stocks, indicating an obvious valuation advantage.

Healthcare Services Life Science Nutraceutical Pharmaceutical